ABSTRACT
@#AIM:To retrospectively analyze the effect of Qiming Granules combined with Deproteinized Calfblood Extract Eye Gel in the treatment of diabetes phaeoemulsification postoperative xerophthalmia.<p>METHODS:From June 2017 to June 2018, 147 diabetics 269 eyes were diagnosed with phaeoemulsification postoperative xerophthalmia were enrolled in our study. The control group was given the Tobramycin Dexamethasone Eye Drops and Diclofenac Sodium Eye Drops, the Sugaojie group was given Deproteinized Calfblood Extract Eye Gel on the basic of the control group, the combined group was given the Qiming Granules on the basic of the Sugaojie group. The courses all last 4wk. The corneal fluorescence staining, BUT and SⅠt were analyzed before, and post 1mo after treatment, and the clinical efficacy of each group was analyzed.<p>RESULTS: There was no difference among three groups on BUT and SⅠt before treatment(<i>P</i>>0.05). After 1 mo treatment, BUT and SⅠt of the Sugaojie group and the combined group were significantly improved compared to the control group(<i>P</i><0.05), furthermore, the combined group did better role on BUT, SⅠt and total effective rate compared to the Sugaojie group(97.9%<i> vs </i>89.0%, <i>P</i>=0.013).<p>CONCLUSION: Qiming Granules combined with Deproteinized Calf blood Extract Eye Gel could improve xerophthalmia after phaeoemulsification surgery. It is a positive and effective treatment, which has good clinical application significance.
ABSTRACT
BACKGROUND@#Microvascular complications in type 2 diabetes (T2DM), including diabatic retinopathy (DR), diabetic kidney disease (DKD), diabetic peripheral neuropathy (DPN) are the leading causes of visual loss, end-stage renal disease or amputation, while the current therapies are still unsatisfactory. Chinese medicine (CM) has been widely used for treating diabetic mellitus. However, most of the previous studies focused on the single complication. The role of CM treatment in T2DM patients with 2 or multiple microvascular complications is not clear.@*OBJECTIVE@#To appraise the curative effect of CM in T2DM patients with 2 or multiple microvascular complications, and to compare the effects of stationary treatment and individualized treatment in T2DM patients with microvascular complications.@*METHODS@#This trial will be an 8-center, randomized, controlled study with 8 parallel groups. A total of 432 patients will be randomized to 8 groups: DR study group (32 cases) and a corresponding control group (32 cases), DR+DKD study group (64 cases) and a corresponding control group (64 cases), DR+DPN study group (64 cases) and a corresponding control group (64 cases), DR+DKD+DPN study group (56 cases) and a corresponding control group (56 cases). The control group will receive stationary treatment, and the study group will receive individualized treatment based on CM syndrome differentiation in addition to stationary treatment. The study duration will be 50 weeks, comprising a 2-week run-in period, 24 weeks of intervention, and 24 weeks of follow-up. The outcomes will assess efficacy of treatment, improvement in CM symptoms, safety assessments, adherence to the treatment, and adverse events.@*CONCLUSION@#This study will provide evidence of evidence-based medicine for CM treatment in two or multiple microvascular complications caused by T2DM. (Registration No. ChiCTR-IPR-15007072).